JP2016531871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531871A5 JP2016531871A5 JP2016517444A JP2016517444A JP2016531871A5 JP 2016531871 A5 JP2016531871 A5 JP 2016531871A5 JP 2016517444 A JP2016517444 A JP 2016517444A JP 2016517444 A JP2016517444 A JP 2016517444A JP 2016531871 A5 JP2016531871 A5 JP 2016531871A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mucositis
- composition according
- haloalkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 22
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 17
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 17
- 201000010927 Mucositis Diseases 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 12
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 12
- 229940123546 E-selectin antagonist Drugs 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 7
- 239000000651 prodrug Substances 0.000 claims description 7
- 102000015689 E-Selectin Human genes 0.000 claims description 6
- 108010024212 E-Selectin Proteins 0.000 claims description 6
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims description 6
- 208000018925 gastrointestinal mucositis Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000002412 selectin antagonist Substances 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010030216 Oesophagitis Diseases 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 208000003265 stomatitis Diseases 0.000 claims description 4
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 229940124761 MMP inhibitor Drugs 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 39
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- OJXGCWQFAGRXFL-AGEIFGMDSA-N CCC(CC(C[C@H]1OC(C(NC(C)=O)OC(CC2CCCCC2)C(O)=O)OC(CO)[C@@H](C)O)C(NCCNC(C(C)(CC)CCOC(C)(C)C)=O)=O)C1OC([C@H](C1O)O)O[C@@H](C)C1O Chemical compound CCC(CC(C[C@H]1OC(C(NC(C)=O)OC(CC2CCCCC2)C(O)=O)OC(CO)[C@@H](C)O)C(NCCNC(C(C)(CC)CCOC(C)(C)C)=O)=O)C1OC([C@H](C1O)O)O[C@@H](C)C1O OJXGCWQFAGRXFL-AGEIFGMDSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361884856P | 2013-09-30 | 2013-09-30 | |
| US61/884,856 | 2013-09-30 | ||
| PCT/US2014/057978 WO2015048616A1 (en) | 2013-09-30 | 2014-09-29 | Methods and compositions for treating and/or preventing mucositis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016531871A JP2016531871A (ja) | 2016-10-13 |
| JP2016531871A5 true JP2016531871A5 (enExample) | 2017-10-05 |
Family
ID=52744558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517444A Pending JP2016531871A (ja) | 2013-09-30 | 2014-09-29 | 粘膜炎を治療および／または予防するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20170296566A9 (enExample) |
| EP (1) | EP3052510A4 (enExample) |
| JP (1) | JP2016531871A (enExample) |
| CN (1) | CN105683208A (enExample) |
| AU (1) | AU2014324634A1 (enExample) |
| CA (1) | CA2925119A1 (enExample) |
| WO (1) | WO2015048616A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2928476T (lt) | 2012-12-07 | 2018-05-25 | Glycomimetics, Inc. | Junginiai, kompozicijos ir būdai, naudojant e-selektino antagonistus, hemopoetinių ląstelių mobilizacijai |
| HUE045542T2 (hu) | 2014-12-03 | 2019-12-30 | Glycomimetics Inc | E-szelektinek és CXCR4 kemokin receptorok heterobifunkcionális inhibitorai |
| BR112018008962A8 (pt) * | 2015-11-03 | 2019-02-26 | Glycomimetics Inc | anticorpos para direcionar células tronco cancerígenas e tratar cânceres agressivos |
| WO2017151708A1 (en) | 2016-03-02 | 2017-09-08 | Glycomimetics, Inc. | Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin |
| US20200316100A1 (en) * | 2016-05-24 | 2020-10-08 | GycoMimetics, Inc. | Haloalkyl fucose-containing selectin antagonists |
| EP3497131B1 (en) | 2016-08-08 | 2022-03-09 | GlycoMimetics, Inc. | Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4. |
| CA3037850A1 (en) | 2016-10-07 | 2018-04-12 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
| CA3054605A1 (en) | 2017-03-15 | 2018-09-20 | Glycomimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
| EP3717013A1 (en) | 2017-11-30 | 2020-10-07 | GlycoMimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
| EP3732186A1 (en) | 2017-12-29 | 2020-11-04 | GlycoMimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
| US11707474B2 (en) | 2018-03-05 | 2023-07-25 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
| EP3893936A2 (en) * | 2018-12-10 | 2021-10-20 | GlycoMimetics, Inc. | Methods of treating hiv and aids and the elimination of latent reservoirs of hiv infection using selectin, galectin, and siglec antagonists |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| JP2022546277A (ja) * | 2019-08-20 | 2022-11-04 | グリコミメティクス， インコーポレイテッド | Ｅセレクチン阻害剤中間体を調製するためのプロセス |
| MX2022015894A (es) * | 2020-06-14 | 2023-01-24 | Glycomimetics Inc | Composiciones y metodos para superar la resistencia mediada por microentorno mediante direccionamiento de e-selectina. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458777B1 (en) * | 1998-03-13 | 2002-10-01 | Mucosal Therapeutics Llc | Methods and compositions for treating and preventing mucositis |
| US7728117B2 (en) * | 2005-09-02 | 2010-06-01 | Glycomimetics, Inc. | Heterobifunctional pan-selectin inhibitors |
| SI2794626T1 (en) * | 2011-12-22 | 2018-02-28 | Glycomimetics, Inc. | E-SELECTINE ANTAGONIST COMPOUNDS |
| WO2015109049A1 (en) * | 2014-01-17 | 2015-07-23 | Glycomimetics, Inc. | E-selectin antagonists modified by macrocycle formation to the galactose |
-
2014
- 2014-09-29 JP JP2016517444A patent/JP2016531871A/ja active Pending
- 2014-09-29 WO PCT/US2014/057978 patent/WO2015048616A1/en not_active Ceased
- 2014-09-29 US US15/025,730 patent/US20170296566A9/en not_active Abandoned
- 2014-09-29 AU AU2014324634A patent/AU2014324634A1/en not_active Abandoned
- 2014-09-29 CN CN201480057818.5A patent/CN105683208A/zh active Pending
- 2014-09-29 EP EP14849941.1A patent/EP3052510A4/en not_active Withdrawn
- 2014-09-29 CA CA2925119A patent/CA2925119A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530549A5 (enExample) | ||
| JP2019529518A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| JP2015078230A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2016506916A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| JP2016534148A5 (enExample) | ||
| JP2011523412A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2015516427A5 (enExample) | ||
| RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2018517686A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| JP2017517565A5 (enExample) | ||
| JP2017141277A5 (enExample) | ||
| JP2017503833A5 (enExample) | ||
| JP2015521195A5 (enExample) | ||
| JP2018521056A5 (enExample) | ||
| JP2016515550A5 (enExample) | ||
| JP2019513829A5 (enExample) | ||
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| EA201692298A1 (ru) | Производные карбоксамидов |